-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Reinstates Neutral on Nektar Therapeutics, Announces $65 Price Target

Benzinga·08/21/2026 19:03:15
Listen to the news
JP Morgan analyst Jessica Fye reinstates Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and announces $65 price target.